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ABSTRACT 
Background: Dermatological methyl-aminolevulinate photodynamic therapy (MAL-
PDT) is utilized to successfully treat dermatological conditions.  This study monitored 
fluorescence changes attributed to the accumulation and destruction of the 
photosensitizer, protoporphyrin IX (PpIX), at several different stages during the first 
and second treatments of clinical dermatological MAL-PDT. 
Methods: A commercially available, non-invasive, fluorescence imaging system 
(Dyaderm, Biocam, Germany) was utilized to monitor fluorescence changes during 
the first and second MAL-PDT treatments in seventy-five lesions.   
Results: The clinical data indicated statistically significant increases in fluorescence 
within lesions following the application of MAL for both treatments (P<0.001 and 
P<0.01 respectively) and subsequent statistically significant decreases in 
fluorescence within the lesions following light irradiation for both treatments (P<0.001 
and P<0.01 respectively) whilst normal skin fluorescence remained unaltered.  
Lesions receiving a second treatment accumulated and dissipated significantly less 
PpIX (P<0.05) than during the first treatment.  No significant differences were noted in 
PpIX accumulation or dissipation during MAL-PDT when gender, age, lesion type and 
lesion surface area were considered.   
Conclusions: It can therefore be concluded that PpIX fluorescence imaging can be 
used in real-time to assess PpIX levels during dermatological PDT.  Similar 
observations were recorded from the three currently licensed indications indicating 
that the standard ‘one size fits all’ protocol currently employed appears to allow 
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adequate PpIX accumulation, which is subsequently fully utilized during light 
irradiation regardless of patient age, gender or lesion surface area.   
 
INTRODUCTION 
Photodynamic therapy (PDT) enables the selective destruction of tumor tissue 
preserving the majority of the surrounding normal tissue (1, 2) and so has huge 
potential as a cancer therapy.  PDT induces the production of highly localized reactive 
oxygen species (ROS) which contribute to cellular damage and ultimately cell death 
via apoptotic, necrotic and autophagic mechanisms (3).  The production of ROS 
during PDT is completely reliant on the presence of three critical components; a 
photosensitizer, light of the appropriate wavelength and molecular oxygen (3).  The 
absence or mistiming of just one of these components results in no ROS production 
/cell death (4). 
 
PDT is now widely employed in treating a variety of different carcinomas, with 
numerous different photosensitizers being available (2, 5, 6).  PDT has found a 
particular niche in the treatment of non-melanoma skin cancers (NMSC) and 
associated pre-cancers which are the most prevalent malignancy in the Caucasian 
population.  In the United States more than one third of all adult cancers are NMSC, 
with between 900,000 to 1,200,000 new cases occurring per year (7).  PDT for NMSC 
utilizes a topical pro-drug (either aminolevulinic acid (ALA) or an ester derivative) 
which results in the accumulation of the endogenous photosensitizer, protoporphyrin 
IX (PpIX), within the tumor cells.  The topical pro-drug is converted enzymatically via 
4 
 
the heme biosynthesis pathway (8) to PpIX (the immediate precursor to heme), which 
accumulates preferentially due to differences in the stratum corneum overlying tumors 
improving prodrug penetration into the lesion and alterations in various enzyme 
activities (8).  The accumulated PpIX is then activated utilizing a red light ( 635 nm) 
and providing sufficient tissue oxygen is present, ROS are produced within the 
diseased cells resulting in cellular damage and subsequent cell death (8).   
 
Topical PDT with ALA (or an ester derivative, in the UK the methyl derivative methyl-
aminolevulinate (MAL) is the licensed pro-drug (Metvix®, Galderma, UK)) has proved 
to be successful in the treatment of NMSC (including superficial basal cell carcinoma 
(sBCC) and Bowen’s disease (BD)) and associated pre-cancers (e.g. actinic keratosis 
(AK)).  The clinical clearance rates are similar to standard treatment methodologies 
for these conditions (e.g. surgical excision and curettage) (9-16).  Furthermore PDT 
negates several other issues that commonly arise in the standard treatment of these 
indications, including lesion size and multiplicity as well as also resulting in a better 
cosmetic outcome (17). 
   
The accumulation and dissipation of the endogenous photosensitizer, PpIX, can be 
followed by exploiting the characteristic fluorescence properties of PpIX (18).  
Excitation of PpIX with blue light (410 nm) results in detectable fluorescence in the red 
region (635 nm and 700 nm) (19).  The fluorescent properties of PpIX are commonly 
employed in photodiagnosis, aiding clinicians in diagnosis and demarcation for 
excision (20, 21).  In pre-clinical studies the fluorescent properties of PpIX are utilized 
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to follow changes in the photosensitizer concentration (22-25).  Whilst non-invasive 
techniques are preferred, clinically to date the majority of information about 
accumulation of the photosensitizer derives from chemical extraction conducted on 
excised tissue followed by high performance liquid chromatography (26, 27).  This 
invasive technique does not enable the photosensitizer to be followed during real-
time, it simply provides information about PpIX concentration  at one specific point 
following the process being terminated.  The non-invasive commercially available 
imaging system employed within this study (Dyaderm, Biocam, Germany) is utilized 
by several groups for photodiagnosis of skin lesions (28, 29).  Following extensive 
validation, this system was considered to be capable of monitoring changes in PpIX 
during real-time MAL-PDT (30).  Whilst numerous factors hinder reproducibility in 
fluorescence imaging (31) it was shown that consistent application resulted in 
reproducible images been acquired of normal human skin (30).   
 
This study utilized the Dyaderm to follow MAL-PDT treatment of licensed indications 
(AK, BD and sBCC) in the dermatology PDT clinic at Royal Cornwall Hospital (Truro, 
UK).  A positive correlation has been previously demonstrated between PpIX 
photobleaching and cellular damage (22, 25, 32, 33), indicating that the greater the 
level of photobleaching the more efficacious the PDT treatment.  This finding 
indicated that greater PpIX accumulation increases the potential of the therapy as 
more PpIX is available for activation during irradiation.  Therefore one of the main 
modalities of treatment enhancement focuses around increasing the level of PpIX 
within cells utilizing a variety of different techniques including lesion preparation (34), 
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alternative prodrugs (35), penetration enhancers (36) and iron chelators (24, 37).  
Hence the identification of general factors that may limit or enhance accumulation and 
dissipation of PpIX is important to establish in order to enable further understanding of 
the treatment process, and further investigation may result in more individualized 
treatment programs being developed in the future.         
 
 
MATERIALS AND METHODS 
Fluorescence imaging:  The study employed a commercially available non-invasive 
fluorescence imaging system (Dyaderm, Biocam, Germany).  The system consisted of 
a Xenon flash light source that has a custom bandpass filter (370-440 nm) that 
alternated between white and blue light (370-440 nm) and a 12-bit Sony charge 
coupled device (CCD) camera combined in one adjustable arm coupled to a Pentium 
IV computer equipped with custom-made image capturing software (Dyaderm Pro v2, 
Biocam, Germany).  Seven light pulses per second were released from the camera to 
the area of interest, and the returning light was collected by the CCD camera 
(exposure time 100 µs) which utilized a special Schott GG 455 longpass filter to 
exclude the excitation light (370-440 nm).  The red pixels of the CCD camera (spectral 
sensitivity of which at 630 nm is between 85% and 90%) were used to generate a 
fluorescence image from the red spectrum fluorescence emitted from the excited 
PpIX.  In this way, a normal colored image (from the white light) and a fluorescence 
image (from the blue light 370-440 nm) were simultaneously collected and processed 
by the system in real time.  The images acquired were magnified by a factor of three.  
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PpIX is not the sole fluorophore within the skin to be activated by blue light; 
lipopigments and flavins both emit light in the green spectrum when excited with blue 
light.  The autofluorescence was also recorded by the camera, enabling changes in 
autofluorescence to be considered during real time MAL-PDT, these were subtracted 
from the PpIX image produced to ensure the sole changes recorded resulted from 
changes in the concentration of the porphyrins.  To ensure the stability of the camera 
a synthetic PpIX fluorescence standard (Biocam, Germany) was imaged on each 
clinic day to ensure the continuity of the system.       
Clinical data capture:  All patients attending for their first routine MAL-PDT appointment 
for licensed indications (AK and biopsy proven BD and sBCC) at our Dermatology 
Department (Royal Cornwall Hospital, Truro, UK) were informed about this ethically 
approved study (Cornwall and Plymouth Research Ethics Committee) and subsequently 
recruited.  The seventy-five recruited patients were treated as for a normal MAL-PDT 
clinic, with any crust overlying the lesion prior to treatment gently removed with curettage.  
The topical pro-drug MAL (commercially available as Metvix®, 160 mg/g MAL, Galderma, 
UK) was then applied to the lesion at approximately 1 mm thickness, with a 5 mm border.  
The lesion was then covered with an occlusive dressing for the three hour application 
period.  Any excess MAL was then wiped away and the lesion irradiated with a standard 
light protocol (Aktilite, Photocure, Norway, 635 +/- 5 nm, 37 Jcm-2, 80 mWcm-2, 
positioned 5-8 cm above the lesion).  Lesions were covered with a dressing to prevent 
any subsequent light exposure as the area was photosensitive for approximately 24 
hours.  The patients’ lesion was imaged at three distinct time points during the treatment 
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process; prior to the application of MAL, after the three hour application of MAL and 
immediately following light irradiation.  Only one lesion was imaged per patient to 
increase statistical power.  The imaging followed the standard protocol derived previously 
within our group which enabled reproducible images to be acquired (30).  Details 
including the patients age, gender, lesion type, location and size were all recorded prior 
to commencement of imaging.  The lesions were treated as per the National Institute of 
Clinical Excellence (NICE) guidelines (38) although all lesion types received two identical 
treatments nine days apart here.  Twenty five of each licensed lesion type were recruited 
and monitored for the two PDT treatments.  When the treatment was complete the 
images were exported for further image analysis.   
Data analysis:  The images were exported as Bitmaps (640*512 pixels - to avoid data 
loss) and analyzed in NIH ImageJ software (http://rsb.info.nih.gov/ij/).   The images were 
analyzed from the same point within the lesion, as previous studies indicated that this 
lowered the coefficient of variance (data not shown) and the mean grayscale values 
recorded for each time point, enabling quantitative analysis of PpIX levels.  These data 
were analyzed for statistical significance via either the repeated measures ANOVA or the 
paired student’s t-test, comparing and contrasting the fluorescence changes observed 
during the first and second PDT treatment cycles, the distribution of the photosensitizer 
and any relationships between changes in accumulation/dissipation and patient gender 
(42 males and 33 females), patient age (patient age range 46-98 years, mean age 77 
years) and lesion size.  Fluorescence distribution was also monitored in all lesions by 
measuring the grayscale values at fourteen locations spiraling out from the lesion centre.  
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RESULTS 
Fluorescence changes within licensed indications during the first and second 
MAL-PDT treatments 
Prior to image acquisition the synthetic PpIX standard was monitored and over the 
course of this study no significant difference in the grayscale intensity was recorded 
(P=0.950, data not shown).  The images acquired from the licensed indications 
indicated that the majority underwent detectable fluorescence changes during the first 
and second MAL-PDT treatments (Figure 1).  Subsequent image analysis 
demonstrated a significant increase in fluorescence intensity within all three distinct 
lesion types following the three hour MAL application (P<0.001 and P<0.01 
respectively, Figures 2a and b).  Following light irradiation a significant decrease 
(P<0.001 and P<0.01 respectively, Figures 2a and b) in the grayscale intensities was 
observed within all three lesion types following light irradiation during both the first and 
second treatments.  In contrast the area of normal skin monitored concurrently 
showed no significant changes in fluorescence during the treatment procedure 
(P=0.839 (1st treatment) and P=0.549 (2nd treatment), data not shown).  For both the 
first and second treatments no significant differences were observed between the 
distinct lesion types in terms of the accumulation (ANOVA; 1st treatment P=0.950; 2nd 
treatment P=0.710) and dissipation (ANOVA; 1st treatment P=0.740; 2nd treatment 
P=0.270) of the photosensitizer (Figure 3).  A positive correlation existed between the 
total PpIX fluorescence after the three hours of MAL application and the fluorescence 
decrease during light irradiation (r2=0.53; data not shown).  The level of PpIX 
accumulation during both the first and second treatments after three hours MAL 
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application was approximately equal (P>0.250) to the dissipation observed during 
light irradiation on each occasion (Figure 4).  However during the second treatment 
the total accumulation/dissipation of PpIX observed was statistically significantly lower 
than when compared to the initial treatment (P<0.01 and P<0.05 respectively for all 
three indications separately (Figure 3)).  Furthermore the area of fluorescence within 
the lesion was found to be significantly smaller (P<0.01) on the second PDT treatment 
(Figure 5) as could be observed visually from the images (Figure 1).  The distribution 
of the photosensitizer was monitored within these lesions by analyzing the grayscale 
intensity of the lesion as you moved away from the centre.  PpIX distribution varied 
greatly, with an approximately equal split between lesions demonstrating no variation 
(n=32, 43%) and lesions demonstrating significant (P<0.01) variation (n=43, 57%).  
Lesions with a surface area of less than 50 mm2, were significantly (P<0.01) more 
likely to have homogenously distributed PpIX (100% versus 21%).   
Relationship of PpIX accumulation and dissipation with patient age, gender and 
lesion size 
The patients were split into four distinct age brackets on the basis of their age (under 60 
(n=14), 60-70 (n=16), 70-80 (n=21) and over 80 (n=24) years of age) and the 
accumulation and dissipation of PpIX fluorescence were compared.  The different age 
groups showed no significant differences in terms of PpIX accumulation (P=0.270) and 
dissipation (P=0.310) (Figure 6).  A direct comparison was also made in terms of 
accumulation between the youngest and oldest groups but no significant difference was 
observed (unpaired t-test, P=0.100).  As observed previously PpIX accumulation 
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approximated to PpIX dissipation in three of the four age groups (P=0.131, P=0.413 and 
P=0.09 for the under 60s, 60-70 and 70-80 age groups respectively); in contrast the 
accumulation in the over 80 age group was observed to be significantly higher than the 
dissipation (P < 0.05).  Patient gender (n=42 (56%) males and n=33 (44%) females) was 
not observed to significantly alter accumulation (P=0.791 and P=0.924) or dissipation of 
PpIX (P=0.391 and P=0.868) during both the first and second PDT treatments 
respectively (Figure 7). No correlate ions were observed between the surface area of the 
lesion and the MAL-PDT induced changes in fluorescence within these lesions (r2 = 0.02 
for accumulation and r2 = 0.01 for dissipation; Figures 8a & 8b respectively).    
 
DISCUSSION 
This investigation has demonstrated the capacity of a non-invasive imaging system 
(Dyaderm) to detect fluorescence changes during standard clinical dermatological MAL-
PDT for licensed indications (AK, BD and sBCC).  The fluorescence changes arise as a 
result of the accumulation and dissipation of porphyrins and previous studies have 
indicated that photosensitizer PpIX is the dominant porphyrin to accumulate within cells 
after MAL application (26, 27); additionally we have tested the imaging system ourselves 
utilizing a synthetic PpIX standard which indicated that the mean grayscale values 
calculated related to the PpIX concentration (30).   
The three licensed lesion types were each observed to undergo two distinct changes 
in fluorescence during the first and second PDT treatments in the majority of cases, 
whilst areas of surrounding normal skin remained unaltered.  Firstly following the 
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three hour MAL application a statistically significant increase in fluorescence was 
observed during both the first and second PDT treatments (Figures 1 & 2).  This 
increase in fluorescence was attributed to the conversion of MAL via the heme 
biosynthesis pathway to the photosensitizer PpIX (9).  The second change in 
fluorescence was observed immediately following light irradiation where statistically 
significant decreases in fluorescence were detected during both the first and second 
treatments (Figures 1 & 2).  The decrease in fluorescence during light treatment was 
attributed to the photobleaching of PpIX as a result of the production of singlet oxygen 
(8).  The fluorescence changes monitored correlated well with our current 
understanding of the accumulation and dissipation of PpIX during standard 
dermatological MAL-PDT (8, 39).  The level of accumulation and dissipation of 
fluorescence in individual lesion types during MAL-PDT was approximately equal with 
no significant difference observed between these two measurements (Figure 3).  This 
indicated that the light irradiation phase was effectively photobleaching all the 
accumulated PpIX within the cells of the lesions.  This suggested that providing three 
hours was the optimal application time for MAL (40), then maximal treatment potential 
was reached in the majority of lesions and increasing the light dose would be 
unnecessary as all the PpIX accumulated was already being fully utilized, as no 
excess PpIX remained after the irradiation period.  Furthermore all three licensed 
lesion types were observed to respond in a similar manner (Figure 4).  However a 
larger sample size (100 of each type of lesion) would be required to exclude a type II 
error.  The accumulation and dissipation of PpIX in the different histological lesions 
might be expected to be similar as the conditions are derived from cells within the 
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epidermis, treated in an identical manner with a standard licensed and well evidenced 
protocol and response rates to this PDT treatment method are similar (7, 13, 41-43).     
It is important to note that inter patient variation was large and whilst the data 
presented here represents all of the lesions monitored, a small number of lesions did 
not follow the general trend of significant accumulation and dissipation of 
fluorescence.  Within the data set there were several examples of lesions which either 
showed limited accumulation and subsequent dissipation of PpIX or demonstrated 
significant accumulation but limited dissipation of the photosensitizer.  These 
anomalies could simply be attributed to inter patient variation; however an underlying 
cause seemed a more likely explanation.  Limited PpIX accumulation could be due to 
inadequate lesion preparation, the application of insufficient pro-drug to the area 
and/or incorrect diagnosis (although sBCC and BD lesions were biopsy proven).  Our 
data collection has also analyzed the role of the practitioner as our service is run with 
several different practitioners (specialized PDT nurses).  However, no significant 
differences were observed between these different practitioners in terms of 
accumulation and dissipation of PpIX (data not shown) suggesting whilst minor 
variations in treatment procedure existed they did not significantly alter the potential 
efficacy of the treatment.  Several factors may be involved in the lesions which 
underwent significant accumulation but limited photobleaching during light irradiation, 
the light placement and the relationship between PpIX concentrations and 
photobleaching.  The light was placed between 5-8 cm away from the lesion surface 
depending on the nurse practitioner and this variation could potentially result in 
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approximately a 10% alteration in the light dosage delivered.  However, the 
dissipation of PpIX was noted to be similar for all practitioners.  Previous in vitro 
studies have indicated that higher PpIX concentrations undergo lower levels of 
photobleaching (22, 44) potentially as a result of saturation of the primary 
photosensitizer binding sites at high concentrations of PpIX therefore PpIX localizes 
at secondary sites which either protect PpIX from singlet oxygen or make it less 
photoactive.  However within this data set a positive correlation was observed 
between the total PpIX fluorescence after three hours of MAL application and PpIX 
photobleaching.  Alternatively other factors may also be involved, especially the 
general health of the patient.      
The second MAL-PDT treatment resulted in lesions undergoing significant changes in 
fluorescence (Figure 2b) indicating that the second treatment was worthwhile.  
However, the accumulation and dissipation of the photosensitizer was significantly 
lower than observed for the first treatment (Figure 3).  This indicated that the first 
treatment effectively destroyed the majority of cancerous and pre-cancerous tissue, 
whilst the second treatment removed the remainder of the diseased cells.  This was 
further represented by the decrease observed in the size of the fluorescent area 
following the application of MAL for the second treatment cycle (Figure 5).  The 
accumulation of PpIX is known to be preferential in tumor tissue when compared with 
normal skin due to the proposed differences in stratum corneum thickness and altered 
enzyme activities (8) hence this data suggests that during the second PDT treatment 
cycle there were areas of normal skin within the lesion borders (to which the prodrug 
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was applied) which no longer preferentially accumulated PpIX in the three hour 
application time.  In fact in our experience there were several cases where visually the 
lesion had improved so significantly following just the first PDT treatment cycle that it 
was barely visible on the second treatment.   
   
The distribution of the photosensitizer following the three hour application of MAL was 
also studied for lesions undergoing the first PDT treatment cycle.  The photosensitizer 
distribution was observed to not alter significantly across the lesion area after the 
three hours of MAL application for 43% of the lesions studied suggesting a 
homogenous photosensitizer distribution as previously noted in basal cell carcinomas 
(36, 40).  The remaining 57% of lesions demonstrated heterogenous PpIX 
fluorescence distribution correlating with previously published observations (45-48).  
On further analysis of the data the surface area of the lesion appeared to contribute to 
the distribution of the photosensitiser with smaller lesions tending to demonstrate a 
more homogenous fluorescence distribution.  The distribution of the photosensitizer is 
of critical importance as it determines the sites of ROS production providing light and 
oxygen are readily available.  It might therefore be interesting to determine in future 
investigations whether lesions with homogenous fluorescence during the first PDT 
treatment respond better to PDT due to a more consistent response across the entire 
lesion.  The photosensitiser distribution was not studied for the second treatment 
cycle as we had previously shown that much less photosensitiser accumulated during 
this second cycle and that the PpIX localized to specific areas which had not been 
successfully cleared during the first treatment cycle.     
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Patient gender was examined as it was proposed that differences in stratum corneum 
thickness and microvasculature may alter the accumulation and dissipation 
respectively.  Previous studies have indicated a weak negative correlation between 
the thickness of the stratum corneum and the PpIX fluorescence observed after 
topical prodrug application (46).  These data demonstrating a difference between 
stratum corneum thickness in males and females is controversial, with data mainly 
supporting no significant differences in the stratum corneum thickness (49-51).  Our 
data demonstrated no significant differences in PpIX accumulation and dissipation for 
males and females (Figure 7) indicating that gender does not significantly alter the 
susceptibility of the skin for MAL uptake or subsequent photosensitizer destruction. 
However, power calculations indicated 600 males and 600 females would be required 
to rule out statistical error in this respect.   The study indicated that the patients’ age 
did not significantly alter the accumulation and dissipation of PpIX during the first 
treatment cycle of MAL-PDT (Figure 6).  However there was a small difference 
between the two extremes of age which was approaching but did not achieve 
statistical significance with this sample size.  This may be due to the thinning of the 
stratum corneum over time and therefore more elderly patients may be more efficient 
at taking up the pro-drug, MAL, enabling higher concentrations of PpIX to accumulate 
within the tumor cells.  This would be interesting to investigate further, however one 
limitation of this data is that relatively few patients fall in the under 60 age bracket 
(19% here) with even fewer under 50 (6% here), hence indicating that investigating 
extremes of age in terms of accumulation would probably lack statistical power.  
Perhaps predictably in light of the data already presented here (with PpIX dissipation 
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mimicking PpIX accumulation) no significant difference was observed when studying 
PpIX dissipation during light irradiation in licensed indications in different age brackets 
(Figure 6).  With the exception of the over 80s age bracket, where accumulation was 
significantly greater than dissipation of PpIX, accumulation approximated to 
dissipation within the age groups (Figure 6).  Significant further study would be 
required to rule out a type II error.  However, it is feasible that more elderly patients 
struggled to completely dissipate the PpIX during light irradiation as a result of the 
altered cutaneous microvasculature that occurs with age, with a general trend towards 
decreased cutaneous perfusion in older individuals (52-55), which potentially lowers 
oxygen availability, therefore potentially reducing oxygen-dependent photobleaching.   
No correlation was observed between the surface area of the lesion and the relative 
levels of accumulation and dissipation of PpIX during MAL-PDT (Figures 8a & 8b).  
This was expected as the entire surface of the lesion was covered with MAL and the 
whole lesion irradiated in accordance with the standard treatment protocol.  
 
Previous studies have shown the relationship between photobleaching of PpIX and 
cellular damage (22, 25, 33, 39) and previous work within our group has linked 
changes in fluorescence intensity recorded with the non-invasive imaging system to 
clinical outcome (56).  The greater the photobleaching of PpIX the greater the 
likelihood a complete clinical clearance of the lesion will occur.  These data presented 
suggest that all licensed indications responded in a similar manner in terms of PpIX 
accumulation and dissipation during MAL-PDT regardless of patient age, gender or 
lesion surface area.    
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In this study, we have observed that statistically significant changes in PpIX 
fluorescence occur during both the first and second MAL-PDT treatments and that all 
three licensed indications (AK, BD and sBCC) responded in a similar manner, 
supporting the one treatment regimen fits all protocol.  We have also demonstrated 
that whilst the second treatment undergoes statistically smaller changes in 
fluorescence intensity than during the first treatment, importantly however, these 
changes were noted to be significant indicating that application of a second treatment 
was efficacious/worthwhile.  Furthermore it was noted that with the sample size 
investigated, patient age, gender and lesion size did not appear to significantly alter 
accumulation and dissipation of the photosensitizer.  These initial data provide an 
insight into photosensitizer accumulation and dissipation during dermatological MAL-
PDT and with further application may be used in the future to evaluate various 
enhancement modalities.   
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FIGURE CAPTIONS 
 
Figure 1.  Fluorescence images acquired from a superficial basal cell carcinoma 
lesion located on the chest of a female patient undergoing the two MAL-PDT 
treatments.  The images were taken at three distinct time points during MAL-PDT 
(from left to right: prior to the application of MAL, after the three hour MAL application 
and immediately after light irradiation).  The PpIX fluorescence intensity is 
represented by the color bar at the bottom of the figure which increases from left to 
right.   
 
Figure 2.  Bar chart indicating the changes in PpIX fluorescence intensity for licensed 
lesions undergoing a) the first MAL-PDT treatment and b) the second treatment of 
MAL-PDT between all lesions at each time point.  The error bars represent the 
standard deviations of the data.      
 
Figure 3.  Bar chart illustrating the average accumulation and dissipation of PpIX 
fluorescence for AK, BD and sBCC lesions during the first and second MAL-PDT 
treatments.  * and + represents a statistically significant decrease in the average 
accumulation and dissipation observed during the second treatment cycle at P < 
0.01and P < 0.05 respectively.  The error bars represent the standard deviations of 
the data.   
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Figure 4. Bar chart comparing the accumulation and dissipation of PpIX fluorescence 
during the first and second MAL-PDT treatments of licensed lesions.  The error bars 
represent the standard deviations of the data.   
 
Figure 5. Bar chart illustrating the mean pixel area of PpIX fluorescence recorded 
from images acquired after the 3 hour MAL application on both the first and second 
MAL-PDT treatments (n = 75).  * indicates statistical significance (P < 0.01).  The 
error bars represent the standard deviations of the data.  
 
Figure 6. Bar chart illustrating the mean accumulation and dissipation of the 
photosensitizer PpIX during real-time MAL-PDT for different patient age groups 
undergoing the first treatment.  + indicates a significant difference between 
accumulation and dissipation of the photosensitizer in the over 80s group (P < 0.05).  
The error bars represent the standard deviation of the data.  
 
Figure 7. Bar chart illustrating the mean PpIX accumulation and dissipation by gender 
during dermatological MAL-PDT for licensed indications (n=75).  The error bars 
represent the standard deviations of the data.   
 
Figure 8. Linear regression graphs illustrating the relationship between the surface 
area of the lesion and a) PpIX accumulation and b) PpIX dissipation during MAL-PDT.  
The line represents the regression with coefficients of a) 0.02 and b) 0.01 
respectively. 
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